# Triastek

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triastek

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.triastek.com
- Total disclosed funding: $82M
- Latest round: Series B (Nov 23, 2021)
- Investors on record: 9

## About

Based in Nanjing, China and established in 2015, Triastek (Nanjing) Pharmaceutical Technology Co., Ltd., trading as Triastek, operates as a 3D printing pharmaceutical professional company that provides 3D printing drug development and equipment. The company is the first Chinese pharmaceutical company to be selected for the U.S. FDA's emerging technology project and its products cover China, the United States, Europe, Canada, and Australia, etc. It is headquartered in Nanjing and has a branch in Shanghai. In March 2023, Bollinger Ingelheim China became the partner of the company. In June 2023, the company was awarded as the "2023 TCT Awards' Best Medical Application Award". In July 2026, it closed a strategic investment.

The company develops (MED) melt extrusion deposition, semi-solid extrusion, micro injection molding and micro-droplet injection technologies. Its product lines cover T19 rheumatoid arthritis, T20 cardiovascular disease and T21 ulcerative colitis, etc. The company has many clients, such as Lilly, Bollinger Ingelheim, Merck, Siemens and Shufang.

The company generates revenue from proprietary drug product development, pharmaceutical technology licensing, drug formulation development services and other related services.

The company will use the latest funding for the construction of its Shanghai International R&D and Production Center, the clinical advancement of its oral peptide pipeline, and the expansion of international collaborative business.

## Funding rounds

- Series B, Nov 23, 2021 — Yunqi Partners, Triwise Capital, MPC
- Series B, Jun 22, 2021, $51M — 5Y Capital, CPE Funds Management, Yunqi Partners, MPC, Dalton Venture, Shanghai Sci-Tech Innovation Center Capital
- Series A, Oct 29, 2020, $15M — Yunqi Partners, Dalton Venture
- Series A, Jun 1, 2018, $16M — 5Y Capital, Volcanics Venture, InnoVision Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Series A
- InnoVision Capital (https://capitalatlas.ai/funds/innovision-capital) — Series A
- Yunqi Partners (https://capitalatlas.ai/funds/yunqi-partners) — Series A, Series B
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A, Series B
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series B
- MPC — Series B
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series B
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B